178 related articles for article (PubMed ID: 23940574)
1. Regulators of global genome repair do not respond to DNA damaging therapy but correlate with survival in melanoma.
Bowden NA; Ashton KA; Vilain RE; Avery-Kiejda KA; Davey RJ; Murray HC; Budden T; Braye SG; Zhang XD; Hersey P; Scott RJ
PLoS One; 2013; 8(8):e70424. PubMed ID: 23940574
[TBL] [Abstract][Full Text] [Related]
2. Nucleotide excision repair gene expression after Cisplatin treatment in melanoma.
Bowden NA; Ashton KA; Avery-Kiejda KA; Zhang XD; Hersey P; Scott RJ
Cancer Res; 2010 Oct; 70(20):7918-26. PubMed ID: 20807809
[TBL] [Abstract][Full Text] [Related]
3. Repair of UVB-induced DNA damage is reduced in melanoma due to low XPC and global genome repair.
Budden T; Davey RJ; Vilain RE; Ashton KA; Braye SG; Beveridge NJ; Bowden NA
Oncotarget; 2016 Sep; 7(38):60940-60953. PubMed ID: 27487145
[TBL] [Abstract][Full Text] [Related]
4. Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy.
Albarakati N; Abdel-Fatah TM; Doherty R; Russell R; Agarwal D; Moseley P; Perry C; Arora A; Alsubhi N; Seedhouse C; Rakha EA; Green A; Ball G; Chan S; Caldas C; Ellis IO; Madhusudan S
Mol Oncol; 2015 Jan; 9(1):204-17. PubMed ID: 25205036
[TBL] [Abstract][Full Text] [Related]
5. A majority of human melanoma cell lines exhibits an S phase-specific defect in excision of UV-induced DNA photoproducts.
Bélanger F; Rajotte V; Drobetsky EA
PLoS One; 2014; 9(1):e85294. PubMed ID: 24416382
[TBL] [Abstract][Full Text] [Related]
6. The involvement of ataxia-telangiectasia mutated protein activation in nucleotide excision repair-facilitated cell survival with cisplatin treatment.
Colton SL; Xu XS; Wang YA; Wang G
J Biol Chem; 2006 Sep; 281(37):27117-25. PubMed ID: 16849332
[TBL] [Abstract][Full Text] [Related]
7. DNA REPAIR. Drugging DNA repair.
Jackson SP; Helleday T
Science; 2016 Jun; 352(6290):1178-9. PubMed ID: 27257245
[No Abstract] [Full Text] [Related]
8. Morphology and genomic hallmarks of breast tumours developed by ATM deleterious variant carriers.
Renault AL; Mebirouk N; Fuhrmann L; Bataillon G; Cavaciuti E; Le Gal D; Girard E; Popova T; La Rosa P; Beauvallet J; Eon-Marchais S; Dondon MG; d'Enghien CD; Laugé A; Chemlali W; Raynal V; Labbé M; Bièche I; Baulande S; Bay JO; Berthet P; Caron O; Buecher B; Faivre L; Fresnay M; Gauthier-Villars M; Gesta P; Janin N; Lejeune S; Maugard C; Moutton S; Venat-Bouvet L; Zattara H; Fricker JP; Gladieff L; Coupier I; ; ; ; Chenevix-Trench G; Hall J; Vincent-Salomon A; Stoppa-Lyonnet D; Andrieu N; Lesueur F
Breast Cancer Res; 2018 Apr; 20(1):28. PubMed ID: 29665859
[TBL] [Abstract][Full Text] [Related]
9. Triptolide induced DNA damage in A375.S2 human malignant melanoma cells is mediated via reduction of DNA repair genes.
Chueh FS; Chen YL; Hsu SC; Yang JS; Hsueh SC; Ji BC; Lu HF; Chung JG
Oncol Rep; 2013 Feb; 29(2):613-8. PubMed ID: 23233170
[TBL] [Abstract][Full Text] [Related]
10. Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells.
Wang QE; Milum K; Han C; Huang YW; Wani G; Thomale J; Wani AA
Mol Cancer; 2011 Mar; 10():24. PubMed ID: 21385444
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study.
Joris S; Denys H; Collignon J; Rasschaert M; T'Kint de Roodenbeke D; Duhoux FP; Canon JL; Tejpar S; Mebis J; Decoster L; Aftimos P; De Grève J
ESMO Open; 2023 Dec; 8(6):102041. PubMed ID: 37852034
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic exploitation of tumor cell defects in homologous recombination.
Powell SN; Kachnic LA
Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
[TBL] [Abstract][Full Text] [Related]
13. ATR kinase inhibition sensitizes quiescent human cells to the lethal effects of cisplatin but increases mutagenesis.
Hutcherson RJ; Kemp MG
Mutat Res; 2019 Nov; 816-818():111678. PubMed ID: 31557599
[TBL] [Abstract][Full Text] [Related]
14. Functional characterization connects individual patient mutations in ataxia telangiectasia mutated (ATM) with dysfunction of specific DNA double-strand break-repair signaling pathways.
Keimling M; Volcic M; Csernok A; Wieland B; Dörk T; Wiesmüller L
FASEB J; 2011 Nov; 25(11):3849-60. PubMed ID: 21778326
[TBL] [Abstract][Full Text] [Related]
15. Differing effects of breast cancer 1, early onset (BRCA1) and ataxia-telangiectasia mutated (ATM) mutations on cellular responses to ionizing radiation.
Mamon HJ; Dahlberg W; Azzam EI; Nagasawa H; Muto MG; Little JB
Int J Radiat Biol; 2003 Oct; 79(10):817-29. PubMed ID: 14630541
[TBL] [Abstract][Full Text] [Related]
16. Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma.
Budden T; van der Westhuizen A; Bowden NA
BMC Cancer; 2018 Jan; 18(1):100. PubMed ID: 29373959
[TBL] [Abstract][Full Text] [Related]
17. RAD52 aptamer regulates DNA damage repair and STAT3 in BRCA1/BRCA2‑deficient human acute myeloid leukemia.
Xu Y; Lin Y; Luo Y; Yang Y; Long B; Fang Z; Liu L; Zhang J; Zhang X
Oncol Rep; 2020 Oct; 44(4):1455-1466. PubMed ID: 32945515
[TBL] [Abstract][Full Text] [Related]
18. Functional profiling of nucleotide Excision repair in breast cancer.
Rajkumar-Calkins AS; Szalat R; Dreze M; Khan I; Frazier Z; Reznichenkov E; Schnorenberg MR; Tsai YF; Nguyen H; Kochupurakkal B; D'Andrea AD; Shapiro GI; Lazaro JB; Mouw KW
DNA Repair (Amst); 2019 Oct; 82():102697. PubMed ID: 31499327
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of Nucleotide Excision Repair Decrease UVB-Induced Mutagenesis-An In Vitro Study.
Fidrus E; Hegedűs C; Janka EA; Paragh G; Emri G; Remenyik É
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562002
[TBL] [Abstract][Full Text] [Related]
20. Malignant melanoma cells acquire resistance to DNA interstrand cross-linking chemotherapeutics by p53-triggered upregulation of DDB2/XPC-mediated DNA repair.
Barckhausen C; Roos WP; Naumann SC; Kaina B
Oncogene; 2014 Apr; 33(15):1964-74. PubMed ID: 23604128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
